FCB-Pharmicell Co Ltd. Report issue

For profit Phase 3
Founded: Seongnam Korea, Republic of (2003)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2007
NCT01392105
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infarction (Phase 3)

Myocardial Infarction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1